Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients

類似資料

• Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
  著者:: Yang, Guangzhong, 等
  出版事項: (2013)
• Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
  著者:: Ashrafi, Farzaneh, 等
  出版事項: (2020)
• Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
  著者:: Hassan Zafar, Mir Sadaqat, 等
  出版事項: (2018)
• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  著者:: Crusoe, Edvan De Queiroz, 等
  出版事項: (2020)
• Cyclophosphamide–bortezomib–dexamethasone compared with bortezomib–dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
  著者:: Figueiredo, A., 等
  出版事項: (2020)